Autologous stem cell transplantation in the management of multiple myeloma

Morie Gertz, Craig B. Reeder

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Autologous stem cell transplantation has been shown to improve the survival in patients with multiple myeloma. Seven randomized clinical trials have been reported demonstrating the superiority of stem cell transplantation in inducing disease responses, increasing complete remissions, and prolonging event-free survival (Table 10.1). Three trials demonstrated significant prolongation of median survival in newly diagnosed patients [1]. The largest of these trials enrolled 401 patients and, compared with standard therapy, prolonged median survival by almost 1 year [2]. The available therapies in the era of these trials, however, did not include the novel agents, thalidomide, lenalidomide, and bortezomib, and some have questioned the rationale for stem cell transplantation with the advent of novel agents.

Original languageEnglish (US)
Title of host publicationMultiple Myeloma: Diagnosis and Treatment
PublisherSpringer New York
Pages101-124
Number of pages24
ISBN (Print)9781461485209, 9781461485193
DOIs
StatePublished - Jan 1 2014

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Autologous stem cell transplantation in the management of multiple myeloma'. Together they form a unique fingerprint.

  • Cite this

    Gertz, M., & Reeder, C. B. (2014). Autologous stem cell transplantation in the management of multiple myeloma. In Multiple Myeloma: Diagnosis and Treatment (pp. 101-124). Springer New York. https://doi.org/10.1007/978-1-4614-8520-9_10